Advanced search
Publication Cover
Journal of Chemotherapy Latest Articles
Submit an article Journal homepage
77
Views
0
CrossRef citations to date
0
Altmetric
Anticancer Original Research Paper

Durable pembrolizumab response in metastatic MSS ARID1A-mutant undifferentiated carcinoma of the esophagus

Zohaib Ijaza Department of Medicine, University of FL College of Medicine, Gainesville, FL, USA
,
Doga Kahramangilb Division of Hematology/Oncology, Department of Medicine, University of Florida, Gainesville, FL, USA;c University of Florida Health Cancer Center, Gainesville, FL, USA
,
Kriti Geraa Department of Medicine, University of FL College of Medicine, Gainesville, FL, USA
&
Ilyas Sahinb Division of Hematology/Oncology, Department of Medicine, University of Florida, Gainesville, FL, USA;c University of Florida Health Cancer Center, Gainesville, FL, USACorrespondence[email protected]
Received 29 Jan 2024, Accepted 04 May 2024, Published online: 16 May 2024

Refrences

  • Shiravand Y, Khodadadi F, Kashani SMA, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022;29(5):3044–3060. doi: 10.3390/curroncol29050247.
  • Marei HE, Hasan A, Pozzoli G, et al. Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired. Cancer Cell Int. 2023; 23(1):64. doi: 10.1186/s12935-023-02902-0.
  • Jung J, Heo YJ, Park S. High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis. J Immunother Cancer. 2023;11(4):e006454. doi: 10.1136/jitc-2022-006454.
  • Ozer M, Vegivinti CTR, Syed M, et al. Neoadjuvant immunotherapy for patients with dMMR/MSI-high gastrointestinal cancers: a changing paradigm. Cancers (Basel). 2023; 15(15):3833. doi: 10.3390/cancers15153833.
  • Zhao JJ, Yap DWT, Chan YH, et al. Low programmed death-ligand 1–expressing subgroup outcomes of first-line immune checkpoint inhibitors in gastric or esophageal adenocarcinoma. J Clin Oncol. 2022;40(4):392–402. doi: 10.1200/JCO.21.01862.
  • Sun J-M, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759–771. Internet [cited 2023 Nov 19]. https://pubmed.ncbi.nlm.nih.gov/34454674/ doi: 10.1016/S0140-6736(21)01234-4.
  • Doki Y, Ajani JA, Kato K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386(5):449–462. doi: 10.1056/NEJMoa2111380.
  • Harada G, Amano MT, Antonacio FF, et al. Dramatic response to pembrolizumab monotherapy in a patient with ARID1A-mutant lung adenocarcinoma: case report. Clin Lung Cancer. 2021;22(5):e708–11–e711. doi: 10.1016/j.cllc.2021.01.011.
  • Hu G, Tu W, Yang L, et al. ARID1A deficiency and immune checkpoint blockade therapy: from mechanisms to clinical application. Cancer Lett. 2020;473:148–155. doi: 10.1016/j.canlet.2020.01.001.
  • Huang J, Koulaouzidis A, Marlicz W, et al. Global burden, risk factors, and trends of esophageal cancer: an analysis of cancer registries from 48 countries. Cancers (Basel). 2021;13(1):141. doi: 10.3390/cancers13010141.
  • Singhi AD, Seethala RR, Nason K, et al. Undifferentiated carcinoma of the esophagus: a clinicopathological study of 16 cases. Hum Pathol. 2015;46(3):366–375. doi: 10.1016/j.humpath.2014.11.021.
  • Wang T, Yu J, Liu M, et al. The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: a meta-analysis of clinical studies. Drug Des Devel Ther. 2019;13:539–553. [cited 2023 Nov 19]. doi: 10.2147/dddt.s189514.
  • Durán M, Faull I, Lastra E, et al. ARID1A genomic alterations driving microsatellite instability through somatic MLH1 methylation with response to immunotherapy in metastatic lung adenocarcinoma: a case report. J Med Case Rep. 2021;15(1):89. doi: 10.1186/s13256-020-02589-1.
  • Jiang T, Chen X, Su C, et al. Pan-cancer analysis of ARID1A alterations as biomarkers for immunotherapy outcomes. J Cancer. 2020;11(4):776–780. doi: 10.7150/jca.41296.
  • Xu S, Tang C. The role of ARID1A in tumors: tumor initiation or tumor suppression? Front Oncol. 2021;11:745187. doi: 10.3389/fonc.2021.745187.
  • Wang L, Qu J, Zhou N, et al. Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers. Biomed Pharmacother. 2020;130:110626. doi: 10.1016/j.biopha.2020.110626.
  • Park Y, Chui MH, Suryo Rahmanto Y, et al. Loss of ARID1A in tumor cells renders selective vulnerability to combined ionizing radiation and PARP inhibitor therapy. Clin Cancer Res. 2019;25(18):5584–5594. doi: 10.1158/1078-0432.CCR-18-4222.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.